Key result
Bioprosthetic valve thrombosis has an incidence of 5.05 per 100-patient-years, with guidelines recommending 3 to 6 months of vitamin K antagonists followed by lifelong aspirin.
Answers are grounded in this paper and cite their sources.
Bioprosthetic valve thrombosis occurs at an incidence of approximately 5.05 per 100-patient-years, contextualizing the current guidelines for antithrombotic management after bioprosthetic mitral valve replacement.
Bioprosthetic valve thrombosis (BPVT) is an uncommon complication of valve replacement, with a recent systematic review and meta-analysis reporting an overall incidence of 5.05 per 100-patient-years.1 Current guidelines for antithrombotic therapy after bioprosthetic mitral valve (MV) replacement reflect a grade 2a recommendation of 3 to 6 months of anticoagulation using a vitamin K antagonist (VKA), with an international normalized ratio (INR) goal of 2.5, followed by lifelong aspirin 75 to 100 mg daily.
No takes yet. Share an insight, caveat, or question.
Sapru et al. (2026) conducted an editorial in Bioprosthetic valve thrombosis. Bioprosthetic valve thrombosis has an incidence of 5.05 per 100-patient-years, with guidelines recommending 3 to 6 months of vitamin K antagonists followed by lifelong aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: